Providence offers free oral, head and neck cancer screenings – OregonLive.com

Providence offers free oral, head and neck cancer screenings
OregonLive.com
Providence Health & Services is offering free screening for oral, head and neck cancer in Northeast Portland on April 19. The cancer is the sixth most common, with about 100,000 patients diagnosed in the United States each year. But the screening only

and more »

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2noj6j6
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Providence offers free oral, head and neck cancer screenings – OregonLive.com

Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis

S09598049.gif

Publication date: May 2017
Source:European Journal of Cancer, Volume 77
Author(s): Leonardo Campiotti, Matteo Basilio Suter, Luigina Guasti, Rocco Piazza, Carlo Gambacorti-Passerini, Anna Maria Grandi, Alessandro Squizzato
PurposeTyrosine kinase inhibitors (TKIs) are the cornerstones of treatment for patients with chronic myeloid leukaemia (CML). In recent years, several studies were conducted to evaluate the safety of TKIs discontinuation. We performed a systematic review of the literature to determine the incidence of CML relapse, to identify possible factors relapse rates and to evaluate the long-term safety in CML patients with stable undetectable BCR-ABL transcript level who discontinued TKIs.DesignStudies evaluating TKIs discontinuation in CML patients with undetectable BCR-ABL transcript level were identified by electronic search of MEDLINE and EMBASE database until May 2015. Weighted mean proportion and 95% confidence intervals (CIs) of CML relapse was calculated using a fixed-effects and a random-effects model. Statistical heterogeneity was evaluated using the I2 statistic.ResultsFifteen cohort studies, for a total of 509 patients, were included. Nine studies were at low-risk of bias. All 15 studies included only patients on imatinib. Overall weighted mean molecular relapse rate of CML was 51% (95% CI 44–58%; I2 = 55). Weighted mean molecular relapse rate at 6-month follow-up was 41% (95% CI 32–51%; I2 = 78). Eighty percent of molecular relapses occurred in the first 6 months. All 509 patients were alive at 2-year follow-up and only one patient (0.8%, 95% CI 0.2–1.8%; I2 = 0) has progressed to a blastic crisis.ConclusionsOur findings suggest that imatinib discontinuation is feasible for the majority of CML patients with stable undetectable BCR-ABL transcript level. Approximately 50% of patients remain therapy-free after imatinib discontinuation. Restarting TKIs therapy was followed by a very high rate of molecular response, with no deaths 2 years after discontinuation.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2ojg4RB
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017

S09598049.gif

Publication date: May 2017
Source:European Journal of Cancer, Volume 77
Author(s): Franz Trautinger, Johanna Eder, Chalid Assaf, Martine Bagot, Antonio Cozzio, Reinhard Dummer, Robert Gniadecki, Claus-Detlev Klemke, Pablo L. Ortiz-Romero, Evangelia Papadavid, Nicola Pimpinelli, Pietro Quaglino, Annamari Ranki, Julia Scarisbrick, Rudolf Stadler, Liisa Väkevä, Maarten H. Vermeer, Sean Whittaker, Rein Willemze, Robert Knobler
In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer–Cutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its consensus recommendations for the stage-adapted selection of management options for these neoplasms. Since then, the understanding of the pathophysiology and epidemiology of MF/SS has advanced, the staging system has been revised, new outcome data have been published and novel treatment options have been introduced. The purpose of the present document is to update the original recommendations bearing in mind that there are still only a limited number of controlled studies to support treatment decisions for MF/SS and that often treatment is determined by institutional experience and availability.This consensus on treatment recommendations was established among the authors through a series of consecutive consultations in writing and a round of discussion. Recommended treatment options are presented according to disease stage, whenever possible categorised into first- and second-line options and supported with levels of evidence as devised by the Oxford Centre for Evidence-Based Medicine (OCEBM).Skin-directed therapies are still the most appropriate option for early-stage MF, and most patients can look forward to a normal life expectancy. For patients with advanced disease, prognosis is still grim, and only for a highly selected subset of patients, prolonged survival can be achieved with allogeneic stem cell transplantation (alloSCT). There is a high need for the development and investigation in controlled clinical trials of treatment options that are based on our increasing understanding of the molecular pathology of MF/SS.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oIr4og
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017

Giant cell tumour of bone in the denosumab era

S09598049.gif

Publication date: May 2017
Source:European Journal of Cancer, Volume 77
Author(s): Lizz van der Heijden, P.D. Sander Dijkstra, Jean-Yves Blay, Hans Gelderblom
Giant cell tumour of bone (GCTB) is an intermediate locally aggressive primary bone tumour, occurring mostly at the meta-epiphysis of long bones. Overexpression of receptor activator of nuclear factor kappa-B ligand (RANKL) by mononuclear neoplastic stromal cells promotes recruitment of numerous reactive multinucleated osteoclast-like giant cells, causing lacunar bone resorption. Preferential treatment is curettage with local adjuvants such as phenol, alcohol or liquid nitrogen. The remaining cavity may be filled with bone graft or polymethylmethacrylate (PMMA) bone cement; benefits of the latter are a lower risk of recurrence, possibility of direct weight bearing and early radiographic detection of recurrences. Reported recurrence rates are comparable for the different local adjuvants (27–31%). Factors increasing the local recurrence risk include soft tissue extension and anatomically difficult localisations such as the sacrum. When joint salvage is impossible, en-bloc resection and endoprosthetic joint replacement may be performed. Local tumour control on the one hand and maintenance of a functional native joint and quality of life on the other hand are the main pillars of surgical treatment for this disease. Current knowledge and development in the fields of imaging, functional biology and systemic therapy are forcing us into a paradigm shift from a purely surgical approach towards a multidisciplinary approach. Systemic therapy with denosumab (RANKL inhibitor) or zoledronic acid (bisphosphonates) blocks, respectively inhibits, bone resorption by osteoclast-like giant cells. After use of zoledronic acid, stabilisation of local and metastatic disease has been reported, although the level of evidence is low. Denosumab is more extensively studied in two prospective trials, and appears effective for the optimisation of surgical treatment. Denosumab should be considered in the standard multidisciplinary treatment of advanced GCTB (e.g. cortical destruction, soft tissue extension, joint involvement or sacral localisation) to facilitate surgery at a later stage, and thereby aiming at immediate local control. Even though several questions concerning optimal treatment dose, duration and interval and drug safety remain unanswered, denosumab is among the most effective drug therapies in oncology.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2ojiLma
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Giant cell tumour of bone in the denosumab era

Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab

alertIcon.gif

Publication date: May 2017
Source:European Journal of Cancer, Volume 77
Author(s): Axel Hauschild, Julia Eichstaedt, Lena Möbus, Katharina Kähler, Michael Weichenthal, Thomas Schwarz, Stephan Weidinger

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oj3MZu
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab

Macrophage activation syndrome: A new complication of checkpoint inhibitors

alertIcon.gif

Publication date: May 2017
Source:European Journal of Cancer, Volume 77
Author(s): Nausicaa Malissen, Julie Lacotte, Aurélie Du-Thanh, Caroline Gaudy-Marqueste, Bernard Guillot, Jean-Jacques Grob

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oIbLMp
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Macrophage activation syndrome: A new complication of checkpoint inhibitors

Judge denies ex-speaker’s bid to relax home confinement – The Herald

images?q=tbn:ANd9GcQ6U7ylzyIDwP6UQ4uQEA_5FYR0saGmxlcWJ90xukWZs_YN61sazPxyeGajLoAODia52cRbeAQx
The Herald
Judge denies ex-speaker’s bid to relax home confinement
The Herald
While in prison, DiMasi was treated for tongue and prostate cancer. In arguing for compassionate release, his lawyers and family members said while his cancer was in remission, the illness had resulted in a narrowing of his esophagus that created a
Judge rejects DiMasi’s request to be placed on curfew for final months of sentenceThe Boston Globe

all 4 news articles »

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2nTyt75
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Judge denies ex-speaker’s bid to relax home confinement – The Herald